ドライアイの世界市場

ドライアイの世界市場は2030年までに110億米ドルに達する見込み

2024年に71億米ドルと推定されるドライアイの世界市場は、2024～2030年の分析期間にCAGR 7.5%で成長し、2030年には110億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるシクロスポリンは、CAGR 5.8%を記録し、分析期間終了時には27億米ドルに達すると予測されます。副腎皮質ステロイド分野の成長率は、分析期間中CAGR 9.2%と推定されます。

米国市場は19億米ドルと推定、中国はCAGR 11.4％で成長予測

米国のドライアイ市場は、2024年に19億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに23億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.9%と7.1%と予測されています。欧州では、ドイツがCAGR 4.9%で成長すると予測されています。

世界のドライアイ市場- 主要動向と促進要因のまとめ

世界のドライアイ事例急増の要因は？

ドライアイ（DED）は、医学的には色覚性角結膜炎と呼ばれ、ライフスタイル、人口統計学的要因、環境的要因の複合的な収束により、世界の有病率の著しい上昇を目の当たりにしています。この慢性的な眼症状は、涙の分泌不足または過剰な蒸発によって引き起こされ、炎症、眼表面の損傷、持続的な不快感をもたらします。50歳以上の人口は特に影響を受けやすく、加齢はDEDの発症率増加の最も重大な要因の一つとなっています。しかし、特にデジタル画面が普及した現在では、若年層も例外ではないです。スクリーンに長時間さらされると、瞬きの回数や涙液膜の安定性が著しく低下し、涙液の蒸発やドライアイの症状を引き起こします。

都市化と公害もまた、ドライアイの急増に拍車をかけています。粒子状物質、低湿度環境、冷暖房への暴露は、眼乾燥を悪化させることが証明されています。さらに、コンタクトレンズの普及、レーシックのような屈折矯正手術、抗ヒスタミン剤や抗うつ剤のような全身性薬剤は、ドライアイの状態を悪化させたり誘発したりすることが知られています。この疾患は、読書、運転、長時間の視覚集中といった日常業務に影響を及ぼし、生活の質や生産性を低下させる。患者やヘルスケアプロバイダーの意識が高まるにつれ、診断率も高まり、効果的で利用しやすい治療ソリューションへの需要が高まっています。

どのような革新がドライアイ管理を変革しているのか？

ドライアイの治療状況は、診断と治療介入の両方における進歩により、急速な変貌を遂げつつあります。診断技術は、伝統的なシルマーテストをはるかに超えて進化しており、臨床医は現在、蒸発性ドライアイの主要な原因であるマイボーム腺機能不全を評価するために、涙浸透圧検査、非侵襲的涙液分解時間分析、マイボグラフィーを活用しています。これらの技術革新により、疾患の正確な亜型分類が可能になり、臨床医はより的を絞った治療法を採用できるようになりました。デジタル画像診断ツールやポイントオブケア分析装置により、診断がより正確かつ迅速になり、病院と外来の両方で利用しやすくなっています。

薬理学的な進歩も治療プロトコルを再定義しています。シクロスポリンAやリフィテグラストなどの抗炎症点眼薬は、炎症に伴う慢性ドライアイを管理する最前線の薬剤として登場しました。これらの薬剤は、人工涙液よりも持続的な緩和をもたらすが、人工涙液は依然として広く使用されているもの、一時的な症状の緩和しかもたらさないです。さらなる技術革新は、薬剤溶出性穿刺プラグやインサートのような徐放性ドラッグデリバリーシステムの台頭で見られ、これらは治療アドヒアランスと患者の転帰を改善します。さらに、強力パルス光（IPL）治療、熱脈動装置、オフィス内での眼腺発現処置などの非薬物療法は、中等度から重度の患者の眼表面の健康回復に役立っています。

多様なセクターはドライアイの課題にどのように取り組んでいるか？

ドライアイの負担の増大は、ヘルスケアシステム、製薬会社、さらには企業の雇用者にも多面的な対応を促しています。ヘルスケアにおいては、早期診断と個別化された管理戦略が強調されています。眼科医や検眼医は、未治療のDEDが長期的な影響を及ぼすことを認識し、定期検診に包括的な眼表面評価を取り入れています。デジタルヘルスプラットフォームの統合により、特に医療サービスが行き届いていない地方では遠隔眼科サービスが遠隔評価を提供し、治療へのアクセスも拡大しています。これらのプラットフォームは、疾患の進行を監視し、服薬アドヒアランスを強化し、環境や行動の改善について患者を教育するのに役立っています。

製薬会社は、ドライアイの特定のサブタイプに合わせた新規化合物、併用療法、生物学的製剤の開発に積極的に投資しています。万能薬から、房水欠乏性ドライアイと蒸発性ドライアイといった個々の疾患の病因に基づいた治療薬へのシフトが顕著です。同時に、眼表面バイオマーカー、人工知能、ビッグデータ解析の活用により、バイオテクノロジー企業と学術研究機関との業界連携が、創薬パイプラインを加速させています。企業部門では、DEDが従業員の福利厚生や生産性に与える影響に対する認識が、スクリーンタイム管理、人間工学の改善、室内空気環境の改善といった職場介入策につながっています。このような分野横断的な取り組みは、ドライアイが単なる医学的症状ではなく、より広範な公衆衛生と生活の質の問題であるという認識の高まりを反映しています。

ドライアイソリューションの市場成長と戦略的投資の原動力は？

ドライアイ市場の成長は、技術革新、有病率の上昇、治療パラダイムの進化に関連するいくつかの要因によって牽引されています。主な要因のひとつは、世界の人口動態の変化による高齢化であり、これは涙の機能障害や眼表面の障害に対する感受性の増加に対応しています。特に都市部や職業環境では、長時間の画面への露出が瞬きの頻度や涙液膜の完全性を損ない続けているためです。このような行動の変化は、DEDの患者層を従来のリスクカテゴリーから大きく広げつつあります。

技術面では、ドラッグデリバリーシステムと診断の持続的な進歩により、治療の普及と患者の転帰の改善が加速しています。規制状況も、新規眼科治療薬の迅速な承認パスにより、技術革新と投資が促進されつつあります。これと並行して、公衆衛生キャンペーン、眼科医療イニシアティブ、専門眼科医療に対する保険適用の改善により、眼科医療に対する認識と検診が高まっています。ドライアイが慢性かつ進行性の疾患であることが認識されるにつれ、ヘルスケア関係者は研究、製品開発、患者教育に多くのリソースを割くようになっています。これらの要因が相まって、世界のドライアイ市場は今後10年間、処方薬と非処方薬の両分野で持続的な成長と多様化が見込まれます。

セグメント

製品タイプ（シクロスポリン、副腎皮質ステロイド、リフィテグラスト、眼潤滑剤、点鼻プラグ、その他の製品タイプ）、剤型（液剤、ゲル剤、軟膏剤、その他の剤型）、流通チャネル（病院薬局、小売薬局、スーパーマーケット／ハイパーマーケット、その他の店舗、オンライン薬局）

調査対象企業の例（全39件）

• AbbVie Inc.
• Akorn Operating Company LLC
• Alcon Inc.
• Aldeyra Therapeutics, Inc.
• Allergan plc（AbbVie）
• Bausch+Lomb Incorporated
• Horus Pharma
• Johnson & Johnson
• Mitotech S.A.
• Nicox S.A.
• Novaliq GmbH
• Novartis AG
• OASIS Medical
• OKYO Pharma Ltd.
• Otsuka Pharmaceutical Co., Ltd.
• Rohto Pharmaceutical Co., Ltd.
• Santen Pharmaceutical Co., Ltd.
• Schwind eye-tech-solutions GmbH
• Sentiss Pharma Pvt. Ltd.
• Surface Ophthalmics, Inc.

関税影響係数

Global Industry Analystsは、本社国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

無料アップデート弊社のお客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。我々の16,491以上のレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Dry Eye Disease Market to Reach US$11.0 Billion by 2030

The global market for Dry Eye Disease estimated at US$7.1 Billion in the year 2024, is expected to reach US$11.0 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Cyclosporine, one of the segments analyzed in the report, is expected to record a 5.8% CAGR and reach US$2.7 Billion by the end of the analysis period. Growth in the Corticosteroids segment is estimated at 9.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.9 Billion While China is Forecast to Grow at 11.4% CAGR

The Dry Eye Disease market in the U.S. is estimated at US$1.9 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 11.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.9% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Dry Eye Disease Market - Key Trends & Drivers Summarized

What Is Fueling the Surge in Dry Eye Disease Cases Worldwide?

Dry Eye Disease (DED), medically referred to as keratoconjunctivitis sicca, is witnessing a significant global rise in prevalence due to multiple converging lifestyle, demographic, and environmental factors. This chronic ocular condition is caused by either inadequate tear production or excessive evaporation, resulting in inflammation, ocular surface damage, and persistent discomfort. Populations over the age of 50 are particularly susceptible, making aging one of the most critical contributors to the growing incidence of DED. However, younger demographics are not exempt, especially given the ubiquity of digital screens. Extended screen exposure significantly reduces blink rate and tear film stability, leading to tear evaporation and dry eye symptoms.

Urbanization and pollution are also contributing to this surge. Particulate matter, low humidity environments, and exposure to air conditioning are proven aggravators of ocular dryness. In addition, the widespread use of contact lenses, refractive surgeries like LASIK, and systemic medications such as antihistamines and antidepressants are known to exacerbate or trigger dry eye conditions. The disease affects daily tasks such as reading, driving, or prolonged visual focus, reducing quality of life and productivity. With awareness rising among both patients and healthcare providers, the rate of diagnosis is increasing, intensifying the demand for effective and accessible therapeutic solutions.

Which Innovations Are Transforming Dry Eye Disease Management?

The treatment landscape for Dry Eye Disease is undergoing rapid transformation, driven by advances in both diagnostics and therapeutic interventions. Diagnostic techniques have evolved far beyond traditional Schirmer tests, with clinicians now utilizing tear osmolarity testing, non-invasive tear break-up time analysis, and meibography to assess meibomian gland dysfunction, a leading cause of evaporative dry eye. These innovations enable precise subtyping of the disease, allowing clinicians to adopt a more targeted approach to therapy. Digital imaging tools and point-of-care analyzers are making diagnostics more accurate, faster, and accessible in both hospital and outpatient settings.

Pharmacological advancements have also redefined treatment protocols. Anti-inflammatory eye drops such as cyclosporine A and lifitegrast have emerged as frontline agents in managing chronic dry eye associated with inflammation. These drugs offer more sustained relief than artificial tears, which, although still widely used, only provide temporary symptomatic relief. Further innovation is seen in the rise of sustained-release drug delivery systems-such as drug-eluting punctal plugs and inserts-which improve therapeutic adherence and patient outcomes. Additionally, non-drug therapies like intense pulsed light (IPL) treatment, thermal pulsation devices, and in-office gland expression procedures are helping restore ocular surface health in patients with moderate to severe disease.

How Are Diverse Sectors Addressing the Challenges of Dry Eye Disease?

The rising burden of Dry Eye Disease is prompting multifaceted responses across healthcare systems, pharmaceutical companies, and even corporate employers. In the healthcare setting, early diagnosis and personalized management strategies are being emphasized. Ophthalmologists and optometrists are incorporating comprehensive ocular surface evaluations into routine checkups, recognizing the long-term implications of untreated DED. The integration of digital health platforms is also expanding access to care, with teleophthalmology services providing remote assessments, especially in underserved and rural regions. These platforms are helping monitor disease progression, reinforce medication adherence, and educate patients on environmental and behavioral modifications.

Pharmaceutical companies are aggressively investing in the development of novel compounds, combination therapies, and biologics tailored for specific subtypes of dry eye. There is a notable shift from one-size-fits-all solutions to therapies based on individual disease etiology, such as aqueous-deficient versus evaporative dry eye. At the same time, industry collaborations between biotech firms and academic research institutions are accelerating discovery pipelines through the use of ocular surface biomarkers, artificial intelligence, and big data analytics. In the corporate sector, awareness of the impact of DED on employee well-being and productivity has led to workplace interventions, such as screen time management, improved ergonomics, and indoor air quality enhancements. These cross-sector initiatives reflect a growing recognition of dry eye as not just a medical condition, but a broader public health and quality-of-life issue.

What Is Driving Market Growth and Strategic Investment in Dry Eye Disease Solutions?

The growth in the dry eye disease market is driven by several factors related to technological innovation, rising prevalence, and evolving treatment paradigms. One of the primary drivers is the global demographic shift toward an aging population, which corresponds with increased susceptibility to tear dysfunction and ocular surface damage. Equally influential is the surge in digital device usage across all age groups, as prolonged screen exposure continues to undermine blink frequency and tear film integrity, especially in urban and professional environments. These behavioral shifts are expanding the DED patient pool far beyond traditional risk categories.

On the technological front, sustained progress in drug delivery systems and diagnostics is accelerating treatment adoption and improving patient outcomes. The regulatory landscape is also becoming more conducive, with expedited approval pathways for novel ophthalmic drugs encouraging innovation and investment. In parallel, there is increasing awareness and screening activity driven by public health campaigns, eye health initiatives, and improved insurance coverage for specialty eye care. As dry eye gains recognition as a chronic and often progressive disease, healthcare stakeholders are allocating greater resources to research, product development, and patient education. These factors are collectively propelling the global dry eye disease market forward, setting the stage for sustained growth and diversification in both prescription and non-prescription segments over the next decade.

SCOPE OF STUDY:

The report analyzes the Dry Eye Disease market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs, Other Product Types); Formulation Type (Liquid, Gel, Ointment, Other Formulation Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

• AbbVie Inc.
• Akorn Operating Company LLC
• Alcon Inc.
• Aldeyra Therapeutics, Inc.
• Allergan plc (AbbVie)
• Bausch + Lomb Incorporated
• Horus Pharma
• Johnson & Johnson
• Mitotech S.A.
• Nicox S.A.
• Novaliq GmbH
• Novartis AG
• OASIS Medical
• OKYO Pharma Ltd.
• Otsuka Pharmaceutical Co., Ltd.
• Rohto Pharmaceutical Co., Ltd.
• Santen Pharmaceutical Co., Ltd.
• Schwind eye-tech-solutions GmbH
• Sentiss Pharma Pvt. Ltd.
• Surface Ophthalmics, Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Dry Eye Disease - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Aging Population and Screen Overuse Trends Propel Growth of Dry Eye Therapeutics Market
  • Advancements in Tear Film Imaging and Diagnosis Accelerate Early Detection and Intervention
  • Increased Use of Digital Devices Strengthens Business Case for Preventive Dry Eye Treatments
  • Rising Adoption of Combination Therapy Approaches Enhances Treatment Outcomes
  • Introduction of Targeted Biologics Drives Innovation in Chronic Dry Eye Management
  • OTC Lubricant and Drop Market Expansion Sustains High Volumes in Mild Dry Eye Segments
  • Advances in Meibomian Gland Dysfunction Therapies Expand Treatment Options for Severe Cases
  • Rise in LASIK and Refractive Surgery Complications Drives Post-Procedure Dry Eye Treatment Demand
  • AI-Powered Ocular Surface Assessment Tools Improve Diagnostic Accuracy and Personalization
  • Global Increase in Contact Lens Usage Highlights Preventive Role of Lubricants and Moisturizers
  • Telemedicine Platforms Expand Access to Eye Care, Enhancing Dry Eye Diagnosis in Underserved Areas
  • Growing Consumer Interest in Natural and Preservative-Free Formulations Creates Niche Opportunities
  • Environmental Pollution and Indoor Air Quality Concerns Contribute to Global Disease Burden
  • Increased Investment in Ocular Inflammation Research Promotes Drug Innovation
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Dry Eye Disease Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Dry Eye Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Dry Eye Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Dry Eye Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Cyclosporine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Cyclosporine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Cyclosporine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Corticosteroids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Corticosteroids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Lifitegrast by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Lifitegrast by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Lifitegrast by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Ocular Lubricant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Ocular Lubricant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Ocular Lubricant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Punctal Plugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Punctal Plugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Punctal Plugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Other Formulation Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Other Formulation Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Other Formulation Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Liquid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Liquid by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Liquid by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Gel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Gel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Gel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Ointment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Ointment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Supermarkets / Hypermarkets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Supermarkets / Hypermarkets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Supermarkets / Hypermarkets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Other Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Other Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Other Stores by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Dry Eye Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• JAPAN
  • Dry Eye Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• CHINA
  • Dry Eye Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 77: China Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• EUROPE
  • Dry Eye Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Dry Eye Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Dry Eye Disease by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Dry Eye Disease by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• FRANCE
  • Dry Eye Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 98: France Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: France Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: France 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 101: France Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• GERMANY
  • Dry Eye Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 107: Germany Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Germany Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Germany 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 110: Germany Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Germany Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Germany 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 116: Italy Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Italy Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Italy 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 119: Italy Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Italy Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Italy 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 122: Italy Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Italy Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Italy 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Dry Eye Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 125: UK Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: UK Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: UK 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 128: UK Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: UK Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: UK 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 131: UK Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: UK Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: UK 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 134: Spain Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Spain Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Spain 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 137: Spain Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Spain Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Spain 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 140: Spain Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Spain Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Spain 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 143: Russia Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Russia Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Russia 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 146: Russia Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Russia Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Russia 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 149: Russia Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Russia Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Russia 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Rest of Europe Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Rest of Europe 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Rest of Europe Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Rest of Europe 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Rest of Europe Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Rest of Europe 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Dry Eye Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Dry Eye Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 162: Asia-Pacific Historic Review for Dry Eye Disease by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Asia-Pacific 15-Year Perspective for Dry Eye Disease by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Asia-Pacific Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Asia-Pacific 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Asia-Pacific Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Asia-Pacific 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Asia-Pacific Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Asia-Pacific 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Dry Eye Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 173: Australia Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Australia Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Australia 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 176: Australia Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Australia Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Australia 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 179: Australia Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Australia Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Australia 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• INDIA
  • Dry Eye Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 182: India Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: India Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: India 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 185: India Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: India Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: India 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 188: India Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: India Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: India 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 191: South Korea Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: South Korea Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: South Korea 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 194: South Korea Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: South Korea Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: South Korea 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 197: South Korea Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: South Korea Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: South Korea 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Rest of Asia-Pacific Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Rest of Asia-Pacific Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 206: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Asia-Pacific Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Rest of Asia-Pacific 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Dry Eye Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 209: Latin America Recent Past, Current & Future Analysis for Dry Eye Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 210: Latin America Historic Review for Dry Eye Disease by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Latin America 15-Year Perspective for Dry Eye Disease by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 212: Latin America Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Latin America Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Latin America 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 215: Latin America Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Latin America Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Latin America 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 218: Latin America Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Latin America Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Latin America 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 221: Argentina Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Argentina Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Argentina 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 224: Argentina Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Argentina Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Argentina 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 227: Argentina Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Argentina Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: Argentina 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 230: Brazil Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Brazil Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: Brazil 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 233: Brazil Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Brazil Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: Brazil 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 236: Brazil Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Brazil Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Brazil 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 239: Mexico Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Mexico Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Mexico 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 242: Mexico Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Mexico Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Mexico 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 245: Mexico Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Mexico Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Mexico 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Latin America Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Latin America 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Latin America Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Latin America 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Latin America Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Latin America Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Latin America 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Dry Eye Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 257: Middle East Recent Past, Current & Future Analysis for Dry Eye Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 258: Middle East Historic Review for Dry Eye Disease by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Middle East 15-Year Perspective for Dry Eye Disease by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 260: Middle East Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Middle East Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Middle East 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 263: Middle East Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Middle East Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Middle East 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 266: Middle East Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Middle East Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Middle East 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 269: Iran Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Iran Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Iran 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 272: Iran Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Iran Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Iran 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 275: Iran Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Iran Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Iran 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 278: Israel Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Israel Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Israel 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 281: Israel Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Israel Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Israel 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 284: Israel Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Israel Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Israel 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Saudi Arabia Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Saudi Arabia 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Saudi Arabia Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Saudi Arabia 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 293: Saudi Arabia Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Saudi Arabia Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Saudi Arabia 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 296: UAE Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: UAE Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: UAE 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 299: UAE Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: UAE Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: UAE 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 302: UAE Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: UAE Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: UAE 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Middle East Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Middle East 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Middle East Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Middle East 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 311: Rest of Middle East Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Middle East Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Middle East 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030
• AFRICA
  • Dry Eye Disease Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 314: Africa Recent Past, Current & Future Analysis for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Africa Historic Review for Dry Eye Disease by Product Type - Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Africa 15-Year Perspective for Dry Eye Disease by Product Type - Percentage Breakdown of Value Sales for Cyclosporine, Corticosteroids, Lifitegrast, Ocular Lubricant, Punctal Plugs and Other Product Types for the Years 2015, 2025 & 2030
  • TABLE 317: Africa Recent Past, Current & Future Analysis for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Africa Historic Review for Dry Eye Disease by Formulation Type - Other Formulation Types, Liquid, Gel and Ointment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Africa 15-Year Perspective for Dry Eye Disease by Formulation Type - Percentage Breakdown of Value Sales for Other Formulation Types, Liquid, Gel and Ointment for the Years 2015, 2025 & 2030
  • TABLE 320: Africa Recent Past, Current & Future Analysis for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Africa Historic Review for Dry Eye Disease by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Africa 15-Year Perspective for Dry Eye Disease by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Supermarkets / Hypermarkets, Other Stores and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION